Determination of Landiolol, an Ultra-Short-acting Β1-Receptor Antagonist, in Human Plasma by Liquid Chromatography–tandem Mass Spectrometry
Qun He,Meiyun Shi,Xidong Liu,Yantong Sun,Lianghai Hu,Yan Yang,J. Paul Fawcett,Jingkai Gu,Limei Zhao
DOI: https://doi.org/10.1016/j.jchromb.2011.12.024
IF: 3.318
2011-01-01
Journal of Chromatography B
Abstract:A method for the determination of landiolol, an ultra-short-acting beta(1)-adrenoreceptor antagonist, in human plasma has been developed and validated. With the addition of pyridostigmine bromide to stabilize landiolol in the blood/plasma samples, and bisoprolol as internal standard, plasma samples were subjected to liquid-liquid extraction with diethyl ether:dicholoromethane (60:40, v/v) prior to assay by liquid chromatography-tandem mass spectrometry. Separation was performed on a TC-C-18 column (150 mm x 4.6 mm, 5 mu m) using a mobile phase of methanol: 10 mM ammonium acetate containing 1% formic acid (65:35, v/v) in a run time of 3.5 min. Detection involved electrospray ionization in the positive ion mode followed by multiple reaction monitoring of the precursor-to-product ion transitions of landiolol at m/z 510.1 -> 157.2 and bisoprolol at m/z 326.3 -> 116.1. The method was linear over the concentration range 0.5-500 ng/ml with a lower limit of quantitation of 0.5 ng/ml. Intra- and inter-day precisions (as relative standard deviation, RSD) were <4.4% and <10.0%, respectively, with accuracy (as relative error, RE) <10.0%. The method was successfully applied to a clinical pharmacokinetic study involving a continuous infusion of landiolol hydrochloride to healthy Chinese volunteers. Crown Copyright (C) 2012 Published by Elsevier B.V. All rights reserved.